植入式心律转复除颤器用于左室功能不全伴或不伴缺血性心脏病的一级预防:11项试验8567例患者的Meta分析
该Meta分析系统纳入11项随机对照试验共8567例左室功能不全患者,其中无缺血性心脏病3128例、缺血性心脏病5439例。无缺血性心脏病患者接受ICD治疗使死亡率降低24%(HR 0.76,95%CI 0.64-0.90,P=0.001),缺血性心脏病患者亦降低24%(HR 0.76,95%CI 0.60-0.96,P=0.02)。作者认为两种病因下均有显著24%死亡率下降,决定一级预防ICD植入时可能不再需要区分病因。
要点
- 无缺血性心脏病患者ICD治疗降低死亡率24%(HR 0.76,95%CI 0.64-0.90,P=0.001)。
- 缺血性心脏病患者ICD植入亦降低死亡率24%(HR 0.76,95%CI 0.60-0.96,P=0.02)。
- 两种病因均有显著24%死亡率下降,决定一级预防ICD时可能不再需区分病因。
核心结论
- 无缺血性心脏病患者在CRT基础上加用ICD治疗显示显著生存获益,这一获益在COMPANION试验中此前从未被明确表述。
- 早在DANISH试验之前,无缺血性心脏病患者的Meta分析已显示死亡率降低,DANISH试验与这些数据一致。
- 两种病因下均有显著的24%死亡率降低,决定一级预防ICD植入时可能不再需要区分病因。
研究设计与样本
- 系统识别所有比较ICD与无ICD用于一级预防的随机对照试验。
- 纳入标准为招募左室功能不全患者、报告全因死亡率、并按是否合并缺血性心脏病分层报告结果(或仅招募伴或不伴缺血性心脏病者)。
- 共纳入11项研究,8567例左室功能不全参与者,其中无缺血性心脏病3128例、缺血性心脏病5439例。
- 主要终点为全因死亡率。
主要发现
- 无缺血性心脏病患者中,ICD治疗使死亡率降低24%(HR 0.76,95%CI 0.64-0.90,P=0.001)。
- 缺血性心脏病患者中,ICD植入(在专门操作下)亦使死亡率降低24%(HR 0.76,95%CI 0.60-0.96,P=0.02)。
关键数值与推荐
- 无缺血性心脏病患者ICD治疗降低死亡率24%(HR 0.76,95%CI 0.64-0.90,P=0.001)。
- 缺血性心脏病患者ICD植入降低死亡率24%(HR 0.76,95%CI 0.60-0.96,P=0.02)。
临床怎么用
- 作者认为,两种病因下均有显著24%死亡率降低,决定一级预防ICD植入时可能不再需要区分病因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Primary prevention implantable cardioverter defibrillators (ICDs) are established therapy for reducing mortality in patients with left ventricular systolic dysfunction and ischaemic heart disease (IHD). However, their efficacy in patients without IHD has been controversial. We undertook a meta-analysis of the totality of the evidence. METHODS AND RESULTS: We systematically identified all RCTs comparing ICD vs. no ICD in primary prevention. Eligible RCTs were those that recruited patients with left ventricular dysfunction, reported all-cause mortality, and presented their results stratified by the presence of IHD (or recruited only those with or without). Our primary endpoint was all-cause mortality. We identified 11 studies enrolling 8567 participants with left ventricular dysfunction, including 3128 patients without IHD and 5439 patients with IHD. In patients without IHD, ICD therapy reduced mortality by 24% (HR 0.76, 95% CI 0.64 to 0.90, P = 0.001). In patients with IHD, ICD implantation (at a dedicated procedure), also reduced mortality by 24% (HR 0.76, 95% CI 0.60 to 0.96, P = 0.02). CONCLUSIONS: Until now, it has never been explicitly stated that the patients without IHD in COMPANION showed significant survival benefit from adding ICD therapy (to a background of CRT). Even before DANISH, meta-analysis of patients without ischaemic heart disease already showed reduced mortality. DANISH is consistent with these data. With a significant 24% mortality reduction in both aetiologies, it may no longer be necessary to distinguish between them when deciding on primary prevention ICD implantation.
引用
- Shun-Shin MJ, Zheng SL, Cole GD, et al. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J. 2017. PMID: 28329280. doi:10.1093/eurheartj/ehx028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。